Table 2.

Univariate and multivariate Cox analyses of the immune-related gene signature in one training set and two validation sets

Variables	Univariate Cox analysis		Multivariate Cox analysis
	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
Training set
Immune-related gene signature (high- vs. low-risk)	2.57 (1.85–3.56)	< 0.001	1.68 (1.11–2.54)	0.013
Age (≥ 65 vs. <65 years)	1.21 (0.88–1.66)	0.235
Gender (male vs. female)	1.05 (0.77–1.43)	0.773
Tumor stage (stage 3–4 vs. 1–2)	2.81 (2.03–3.88)	< 0.001	1.69 (1–2.86)	0.051
T (T 3–4 vs. 1–2)	2.41 (1.61–3.60)	< 0.001	1.48 (0.9–2.44)	0.123
M (positive vs. negative)	1.86 (1.06–3.25)	0.03	1.05 (0.53–2.06)	0.896
N (positive vs. negative)	2.64 (1.93–3.62)	< 0.001	1.71 (1.09–2.66)	0.019
Smoking (yes vs. no)	0.89 (0.57–1.41)	0.627
Validation set 1
Immune-related gene signature (high- vs. low-risk)	9.11 (3.21–25.82)	< 0.001	8.63 (2.95–25.21)	< 0.001
Age (≥ 65 vs. <65 years)	1.89 (0.96–3.71)	0.066
Gender (male vs. female)	1.52 (0.78–2.96)	0.219
Smoking (yes vs. no)	1.64 (0.84–3.20)	0.15
KRAS mutation (yes vs. no)	0.87 (0.27–2.85)	0.817
EGFR mutation (yes vs. no)	0.47 (0.24–0.93)	0.03	0.86 (0.43–1.73)	0.673
Validation set 2
Immune-related gene signature (high- vs. low-risk)	2.80 (1.87–4.17)	< 0.001	2.38 (1.57–3.62)	< 0.001
Age (≥ 65 vs. <65 years)	1.38 (0.89–2.14)	0.151
Gender (male vs. female)	1.55 (1.07–2.25)	0.02	1.42 (0.97–2.09)	0.075
Smoking (yes vs. no)	1.37 (0.60–3.14)	0.459
Tumor stage (stage 3–4 vs. 1–2)	2.61 (1.74–3.91)	< 0.001	2.63 (1.74–3.97)	< 0.001
KRAS mutation (yes vs. no)	1.46 (1.00–2.12)	0.049	1.1 (0.74–1.62)	0.643
EGFR mutation (yes vs. no)	0.26 (0.10–0.71)	0.008	0.4 (0.14–1.10)	0.077
TP53 mutation (yes vs. no)	1.24 (0.82–1.86)	0.313

CI confidence interval